Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC-MAGE
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
ALVAC-MAGE is a recombinant canarypox virus–based cancer vaccine designed to stimulate immune responses against tumor cells by expressing human tumor-associated MAGE (Melanoma Antigen Gene) antigens. The construct encodes minigenes for two immunogenic peptides, MAGE-3(168-176) and MAGE-1(161-169), presented on HLA-A1 and B35. Administration of ALVAC-MAGE aims to induce cytolytic T lymphocyte (CTL) responses targeting melanoma cells expressing these MAGE antigens. Developed for advanced melanoma and evaluated in clinical studies, ALVAC-MAGE has shown the ability to induce antitumor immune responses and can be given intradermally or subcutaneously.
- Brand names
- ALVAC mini-MAGE-1/3
- Other names
- ALVAC mini-MAGE-1/3ALVAC-MAGE
02
Targets
MAGEA9 (Melanoma-associated antigen A9)MAGEA6 (Melanoma-associated antigen A family member 6)MAGEA2 (Melanoma-associated antigen 2)MAGEA1 (Melanoma-associated antigen 1)MAGEA12 (Melanoma-associated antigen family A member 12)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on ALVAC-MAGE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC-MAGE.